50 results
SC 14D9
NGM
Ngm Biopharmaceuticals Inc
8 Mar 24
Tender offer solicitation
5:21pm
an update on the Company’s strategy and, with respect to one party, to express its possible interest in a “reverse merger,” and that in each case he … a press release outlining, among other things, the Company’s evolved strategy for aldafermin and NGM120 to focus on rare conditions with significant unmet
SC TO-T
EX-99
NGM
Ngm Biopharmaceuticals Inc
8 Mar 24
Third party tender offer statement
4:53pm
and urgency into life-changing medicines. NGM’s strategy is built on a straightforward central premise: create an environment that both allows drug discovery
424B5
NGM
Ngm Biopharmaceuticals Inc
4 Aug 23
Prospectus supplement for primary offering
5:01pm
in financial losses that could materially impair our ability to pursue our growth strategy, cause the price of our common stock to decline, delay
8-K
EX-99.1
u99zag79 4hfj3hs6
4 May 23
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
4:11pm
8-K
0v0st57ntd azr2ph
4 Apr 23
Cost Associated with Exit or Disposal Activities
4:06pm
8-K
EX-99.1
goo2qirxq7
4 Apr 23
Cost Associated with Exit or Disposal Activities
4:06pm